Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.42 -0.6  -11.1%

Last Trade - 12/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £76.8m
Enterprise Value £11.9m
Revenue £n/a
Position in Universe 5145th / 6825

BRIEF-Aprea Therapeutics Announces Results From Phase 3 Trial Of Eprenetapopt In Myelodysplastic Syndromes

Mon 28th December, 2020 1:14pm
Dec 28 (Reuters) - Aprea Therapeutics Inc  APRE.O :
    * APREA THERAPEUTICS ANNOUNCES RESULTS OF PRIMARY ENDPOINT
FROM
PHASE 3 TRIAL OF EPRENETAPOPT IN TP53 MUTANT MYELODYSPLASTIC
SYNDROMES (MDS)
    * APREA THERAPEUTICS INC - TRIAL FAILED TO MEET ITS PRIMARY
ENDPOINT OF COMPLETE REMISSION (CR) RATE
    * APREA THERAPEUTICS - CR RATE WAS 53% HIGHER IN
EPRENETAPOPT WITH
AZA ARM COMPARED TO AZA ALONE, BUT DID NOT REACH STATISTICAL
SIGNIFICANCE

Source text for Eikon:  ID:nGNX5XmQc3 
Further company coverage:  APRE.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.